NCT04375267 2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1 Completed
Clinical Trials
11 trialsNCT07404176 2026-02-11
TENET
Tata Memorial Hospital
Phase 2 Recruiting
NCT07121478 2025-10-01
Patients With High-grade Pancreatic Neuroendocrine Tumors
National Cancer Center, Korea
Phase 2 Enrolling by invitation
NCT07185672 2025-09-22
PReCedeNT
Tata Memorial Hospital
Phase 3 Recruiting
NCT01673906 2025-06-24
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
Azienda USL Reggio Emilia - IRCCS
Phase 2 Completed
NCT02125474 2019-11-14
Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate
Instituto Nacional de Cancerologia, Columbia
Phase NA Completed
NCT04152928 2019-11-06
Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities
Tel-Aviv Sourasky Medical Center
Phase NA Unknown
NCT04154241 2019-11-06
Developing a Method Using PET-MR to Improve Staging and Monitoring of Neuroendocrine Tumor
Tel-Aviv Sourasky Medical Center
Phase NA Unknown
NCT03963193 2019-05-24
Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
Henan Cancer Hospital
Phase 2 Unknown
NCT02621541 2016-01-06
Nonfunctional Pancreatic NET and PET Imaging
Turku University Hospital
Phase 4 Unknown
NCT01931488 2013-08-29
124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown